연구성과로 돌아가기

2023 연구자 정보 (28 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Kim, I-H.
(Kim, IH) ⓘ 		Catholic Univ Korea, Coll Med, Songeui Med Campus, Med Oncol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Kim, S. Y.
(Kim, SY) ⓘ 		IMBdx Inc, Dept Res, Seoul, South Korea
Chonnam Natl Univ, Ctr Precis Neutrino Res, Dept Phys, Gwangju 61186, South Korea ⓘ 		LLK-4732-2024
Kim, Il Young ⓘ
ⓘ 		[JCR상위 1.1] Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
[JCR상위 74.3] In situ measurement of relative attenuation length of gadolinium-loaded liquid scintillator using source data at RENO experiment ⓘ 		SCIE ⓘ 1.1 ONCOLOGY
INSTRUMENTS & INSTRUMENTATION ⓘ 		hyunsookim@sejong.ac.kr; ⓘ
Kim, Seung Cheol
(Kim, SC) ⓘ 		Pusan Natl Univ Hosp, Pusan, Pusan Jikhalsi, South Korea ⓘ H-1652-2016
Kim, Seung-Cheol ⓘ
ⓘ 		[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus ⓘ SCIE ⓘ 1.1 OBSTETRICS & GYNECOLOGY ⓘ ⓘ
Kim, T-Y.
(Kim, TY) ⓘ 		Seoul Natl Univ, Dept Internal Med, Seoul, South Korea
IMBdx Inc, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Kim, Y-C.
(Kim, YC) ⓘ 		제1저자 Chonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, Hwasun, South Korea
Chonnam Natl Univ, Hwasun Hosp, Gwangju, Hwasun, South Korea ⓘ 		J-2744-2012
Kim, Young ⓘ
ⓘ 		[JCR상위 1.1] Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Kim, Y. W.
(Kim, YW) ⓘ 		Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea ⓘ IAP-6721-2023
Kim, Chang Gon ⓘ
ⓘ 		[JCR상위 1.1] Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Klumpen, H. J.
(Klumpen, HJ) ⓘ 		Vrije Univ, Med Oncol Dept ment, Amsterdam UMC, Med Ctr VUmc, Amsterdam, Netherlands ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966 ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Ko, Hyun Sun
(Ko, HS) ⓘ 		Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Seoul, Seoul Tukpyolsi, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus ⓘ SCIE ⓘ 1.1 OBSTETRICS & GYNECOLOGY ⓘ ⓘ
Kwon, Ji Young
(Kwon, JY) ⓘ 		Catholic Univ Korea, Coll Med, Eunpyeong St Marys Hosp, Seoul, Seoul Tukpyolsi, South Korea ⓘ HJG-4704-2022
Kwon, Ji Young ⓘ
ⓘ 		[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus ⓘ SCIE ⓘ 1.1 OBSTETRICS & GYNECOLOGY ⓘ ⓘ
Lee, E-J.
(Lee, EJ) ⓘ 		Daegu Fatima Hosp, Fatima Res Inst, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] CHEMOKINE RECEPTOR CXCR7 CONTRIBUTE TO THE INFLAMMATORY REACTION OF ARTICULAR CHONDROCYTE ⓘ SCIE ⓘ 1.1 ORTHOPEDICS;RHEUMATOLOGY ⓘ ⓘ
Lee, J-Y.
(Lee, JY) ⓘ 		Yonsei Univ, Gynecol Canc Ctr, Seoul, South Korea ⓘ I-7171-2015
Lee, Jeeyun ⓘ
ⓘ 		[JCR상위 1.1] A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Lee, Joon Ho
(Lee, JH) ⓘ 		Yonsei Univ, Coll Med, Yonsei Univ Hlth Syst, Seoul, Seoul Tukpyolsi, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus ⓘ SCIE ⓘ 1.1 OBSTETRICS & GYNECOLOGY ⓘ ⓘ
Lee, K-W.
(Lee, KW) ⓘ 		Seoul Natl Univ, Internal Med Dept, Bundang Hosp, Seongnam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis ⓘ SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Lee, Keun Seok
(Lee, KS) ⓘ 		Natl Canc Ctr, Gyeonggi Do, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 ⓘ 		SCIE ⓘ 1.1 ONCOLOGY ⓘ ⓘ
Lee, Kyung A.
(Lee, KA) ⓘ 		Kyung Hee Univ, Sch Med, Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.1] Impacts of tocolytics on maternal and neonatal glucose levels in women with gestational diabetes mellitus ⓘ SCIE ⓘ 1.1 OBSTETRICS & GYNECOLOGY ⓘ ⓘ
페이지 이동: